Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

Clinical trial NCT06570447 · RECRUITING

Trial details

NCT number: NCT06570447
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-Cell Lymphoma-Recurrent Diffuse Large B-Cell Lymphoma-Refractory

Start date: 2025-02-27
Primary completion: 2026-12-31
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.